Clinical trials: Glial Tumors
Central Malignant Tumors, PCNSL
A Nomogram for Predicting the Diagnosis of Central Malignant Tumors Based on Preoperative Clinical Characteristics and Laboratory Indicators:
The purpose of this study is to develop a nomogram to predict the diagnostic probability of preoperative central lymphoma and glioma, as well as the diagnostic probability of glioblastoma and non glioblastoma in central malignant…
- Conditions
- Central Malignant Tumors, PCNSL, Glioma, GBM
- Trial name
- PCNSL，GLIOMA (NCT06914700)
- Volunteers
- 800 people
- Sponsor
- Guangdong Provincial People's Hospital
Glioblastoma Multiform, Recurrent Glioblastoma
Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients
Glioblastoma multiform is one of the most invasive and deadly cancers that progresses rapidly and leads to death. Surgery with radiotherapy /chemotherapy, as a treatment approach is ineffective in some cases and is associated…
- Trial name
- NCT05108012
- Testing
- NK cell therapy
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Royan Institute
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma
Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery
This phase I trial studies the side effects and the safety of injecting HSV1716 (a new experimental therapy) into or near the tumor resection cavity. The injection will be done at the time of surgery.
- Conditions
- Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Giant Cell Glioblastoma
- Trial name
- NCT02031965
- Testing
- oncolytic HSV-1716, dexamethasone, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Pediatric Brain Tumor Consortium
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
The BIOMEDE 2.0 study is the second stage of the BIOMEDE multi-arm, multistage rolling programme (adaptive platform protocol). It is a multicenter, randomized, open-label, controlled phase-3 trial evaluating efficacy of ONC201 in…
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered
- Trial name
- BIOMEDE 2 (NCT05476939)
- Testing
- Everolimus, ONC201, Radiotherapy
- Where
- 56 sites in Belgium, Denmark and 6 more
- Volunteers
- 433 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
FUS Etoposide for DMG
The blood brain barrier (BBB) prevents some drugs from successfully reaching the target tumor. Focused Ultrasound (FUS) using microbubbles and neuro-navigator controlled sonication is a non-invasive method of temporarily opening…
- Trial name
- NCT05762419
- Testing
- Etoposide; Oral, 50 Mg, Focused ultrasound with neuro-navigator-controlled sonication
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Columbia University
Glioblastoma, Gliosarcoma
Dose-Intense Temozolomide in Recurrent Glioblastoma
Temozolomide (Temodar) is an FDA approved medication for the treatment of newly diagnosed glioblastomas. In this study, we will be using temozolomide to treat recurrent glioblastomas.
- Trial name
- NCT00657267
- Testing
- Temozolomide
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- Patrick Y. Wen, MD
Brain Cancer
Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas
This is a pilot study. The purpose of this study is to test if an imaging tracer, not approved by the FDA, called 11C-Choline (11C-CH) is useful for evaluating your type of cancer. This tracer is used to perform PET scans.
- Trial name
- NCT02849171
- Testing
- PET scan, C-Choline
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma, IDH-wildtype
Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma
Glioblastoma (GBM) is the primary intracranial malignant tumor with the highest morbidity and mortality, and the 5-year survival rate is less than 10%.
- Trial name
- NCT06327451
- Testing
- Atorvastatin 20mg
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University General Hospital
Glioma, Malignant
18F-FET-PET/MRI vs Standard MRI Alone for Stereotactic RadioTherapy Planning for High Grade Brain Gliomas
Amino acid PET imaging for brain gliomas is gaining acceptance for the diagnosis and monitoring of disease. This is commonly performed in Europe.
- Trial name
- FETSMaRT (NCT06499831)
- Testing
- 0-(2-18F-Fluoroethyl)-L-Tyrosine
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Glioblastoma Multiforme
A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
This study is a multicenter randomized double-blinded controlled phase 2 study evaluating the efficacy and safety of the anti-CMV drug valganciclovir vs placebo as add-on therapy in patients with glioblastoma.
- Trial name
- VIGAS2 (NCT04116411)
- Testing
- Valganciclovir Tablets, Temozolomide 120 mg, Radiotherapy 60 Gy
- Where
- 3 sites in Norway, Sweden
- Volunteers
- 220 people
- Sponsor
- Cecilia Soderberg-Naucler
Astrocytoma, Oligoastrocytoma
FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma
The aim of the study is to compare the two imaging modalities perfusion weighted MR-imaging and FET-PET in their ability to provide an accurate histological evaluation of low grade glioma and to reveal focal abnormalities within…
- Conditions
- Astrocytoma, Oligoastrocytoma, Oligodendroglioma
- Trial name
- NCT01089244
- Where
- 2 sites in Germany
- Volunteers
- 38 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of zedoresertib combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and…
- Trial name
- NCT05765812
- Testing
- Zedoresertib, Temozolomide, Radiotherapy
- Where
- 16 sites in United States, Spain and 1 more
- Volunteers
- 116 people
- Sponsor
- Debiopharm International SA
Central Nervous System Neoplasms
Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients
This study will compare the use of two contrast agents to analyze blood flow characteristics of brain tumors.
- Trial name
- NCT02095353
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Nebraska
Brain Cancer, Brain Neoplasm
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies.
- Conditions
- Brain Cancer, Brain Neoplasm, Glioma, Glioblastoma
- Trial name
- CAPTIVE (NCT02798406)
- Testing
- DNX-2401, pembrolizumab
- Where
- 15 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- DNAtrix, Inc.
Recurrent Glioblastoma, IDH-Wildtype
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
This phase II trial compares the safety, side effects and effectiveness of atezolizumab with tiragolumab to atezolizumab alone in treating patients with glioblastoma that has come back after a period of improvement (recurrent).
- Trial name
- NCT06328036
- Testing
- Atezolizumab, Biospecimen Collection, Magnetic Resonance Imaging
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
This early phase I trial tests the use of a radioactive tracer (a drug that is visible during an imaging test) known as 18F-FMAU, for imaging with positron emission tomography/computed tomography (PET/CT) in patients with brain…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Glioma, Malignant Brain Neoplasm
- Trial name
- NCT04752267
- Testing
- Computed Tomography, 18F-FMAU, Multiparametric Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Glioma of Brain, Recurrence
Efficacy of Kangliuwan for Recurrent Grade IV Glioma
A Prospective Exploratory Clinical Study to explore the efficacy of Hospital Traditional Chinese Medicine Preparation Kangliuwan for Recurrent Grade IV Glioma.
- Trial name
- NCT03949192
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuanwu Hospital, Beijing
Glioma Glioblastoma Multiforme
[18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )
Subjects with histologically proven glioblastoma (GBM) who are suspected to have progression and are candidates for a surgical resection according to standard of care may be eligible for this study.
- Trial name
- Axumin (NCT03990285)
- Testing
- Axumin, Intravenous Solution
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ali Nabavizadeh
Brain and Central Nervous System Tumors
Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Biological therapies such as poly-ICLC use different ways to stimulate the immune system and stop tumor cells from growing. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- Poly-ICLC (NCT00052715)
- Testing
- poly ICLC
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioma
A Study in Subjects With Recurrent Malignant Glioma
An open-label phase 2, multicenter study in participants with recurrent malignant glioma.
- Trial name
- NCT01137604
- Testing
- Lenvatinib, Bevacizumab
- Where
- 5 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Eisai Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.